ĐẶC ĐIỂM SỬ DỤNG THUỐC CHỐNG ĐÔNG Ở NHỮNG NGƯỜI BỆNH CÓ CHỈ ĐỊNH THỦ THUẬT CẤY MÁY TẠO NHỊP VĨNH VIỄN TẠI VIỆN TIM MẠCH VIỆT NAM

Abstract

Objective: Research with the main objective is to find out the characteristics of anticoagulant drug use in patients who are indicated for the permanent pacemaker implantation at the Vietnam National Heart Institute. Methods: Cross-sectional, prospective descriptive study. Study on the patients who are indicated for the permanent pacemaker implantation at the Vietnam National Heart Institute during the period from August 2019 to March 2020. Results: Study on the 294 patients who are indicated for the pacemaker implantation obtained the following results: Number of patients who used anticoagulants and antiplatelet accounted for 36.4%, of which the number of patients using 2 drugs accounted for 6.5%. Around the process of implantation, patients were given vitamin K antagonists and NOACs with the highest rate of 13.3%, dual antiplatelet drugs was 8.5%, single antiplatelet drugs were 9.2%, Low Molecular Weight Heparin (LMWH) is 5.4%. Among patients taking oral anticoagulants, 33.3% continued to maintain NOACs, vitamin K antagonists, 64.0% continued to maintain dual antiplatelet drugs, and 63% continued to maintain single antiplatelet drugs and 18.8% maintained LMWH during implantation. When transplanting, INR index is mainly within safe limit (INR < 1.5) accounting for 96.6%, only 3.4% have INR ≥ 1.5 in which the largest INR value is 3.95. Analgesic drugs used after implantation are mainly first- and second-line analgesics, in no case requiring the use of tertiary analgesia.